Barreras para el inicio del tratamiento antirretroviral en pacientes con virus de la inmunodeficiencia humana e indicación de tratamiento en España. ¿Por qué no inician tratamiento quienes lo tienen indicado? Estudio Bridgap

Viciana-Fernández, Pompeyo; Falcó, Vicenç; Castaño, Manuel; Santos-Gil, Ignacio de los; Olalla-Sierra, Julián; Hernando, Asunción; Deig, Elisabet; Clotet , Bonaventura; Knobel, Hernando; Podzamczer, Daniel; Pedrol, Pere Domingo.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 33(6): 397-403, jun.-jul. 2015. tab, ilus
Artículo en Español | IBECS (España) | ID: ibc-142122

Documentos relacionados

  1. Profound phenotypic and epigenetic heterogeneity of the HIV-1-infected CD4<sup>+</sup> T cell reservoir.
  2. Silence, escape and survival drive the persistence of HIV.
  3. Non-adherence to antiretroviral treatment among migrating fishermen in western Kenya's islands: a rapid qualitative study.
  4. Individual and Collective Forms of Stigma Resistance: Pathways Between HIV and Sex Work Stigma and Viral Suppression Among Female Sex Workers in the Dominican Republic.
  5. Evaluation of a Linkage to care Quality Improvement Initiative for People with HIV.
  6. A Network Immuno-Epidemiological HIV Model.
  7. Demand creation for HIV testing services: A systematic review and meta-analysis.
  8. Relationship Power, Antiretroviral Adherence, and Physical and Mental Health Among Women Living with HIV in Rural Kenya.
  9. Evolving mechanisms and presentations of cardiovascular disease in people with HIV: implications for management.
  10. Ageing with HIV: challenges and coping mechanisms of older adults 50 years and above living with HIV in Uganda.